What is oncolytic immunotherapy?

Oncolytic immunotherapy uses modified viruses to selectively infect and kill cancer cells. These viruses are engineered to also stimulate the immune system to recognize and attack the tumor, offering a two-pronged approach to fighting cancer.

What is Breakthrough Therapy Designation?

Breakthrough Therapy Designation is granted by the FDA to expedite the development and review of drugs that may demonstrate substantial improvement over available therapies for serious conditions.

What is a Complete Response Letter (CRL)?

A CRL is issued by the FDA when it determines that a BLA is not ready for approval. It outlines the specific deficiencies that must be addressed before the drug can be considered for approval.

What is oncolytic immunotherapy?

Oncolytic immunotherapy uses modified viruses to selectively infect and kill cancer cells. These viruses are engineered to also stimulate the immune system to recognize and attack the tumor, offering a two-pronged approach to fighting cancer.

What is Breakthrough Therapy Designation?

Breakthrough Therapy Designation is granted by the FDA to expedite the development and review of drugs that may demonstrate substantial improvement over available therapies for serious conditions.

What is a Complete Response Letter (CRL)?

A CRL is issued by the FDA when it determines that a BLA is not ready for approval. It outlines the specific deficiencies that must be addressed before the drug can be considered for approval.

Back to Trending News

Published: RecentDownload AppJoin Telegram

Replimune's Melanoma Treatment Faces FDA Setback, Threatening Future Development

#biotechnology#FDA#melanoma#oncology#pharmaceuticals#Replimune#drug approval#cancer treatment

Download App Join Community

JIADE Shifts Focus: From Growth at All Costs to 'Scale and Efficiency'

11 Apr 2026Read Article